The company said that results from the artificial intelligence (AI)-Emerge study will show that the company's multiomics blood test can detect colorectal advanced adenomas with 41% sensitivity and 90% specificity. Freenome said these figures are comparable to existing noninvasive tests for colorectal cancer screening.

For example, Freenome said the results from AI-EMERGE show higher sensitivity than stool-based tests like fecal immunochemical tests (41% versus 24%), and comparable sensitivity to fecal immunochemical-DNA tests (41% versus 42%).

The company said its multiomics approach -- which combines signatures from tumor- and nontumor-derived sources -- enabled detection of twice as many advanced adenomas as cell-free DNA methylation-only or single-protein approaches.